高敏肌钙蛋白在疑似心肌梗死中的应用
该研究在15个国际队列的22651例疑似心肌梗死急诊患者中,评估高敏肌钙蛋白I或T在就诊时及早期或晚期连续采样的诊断和预后价值。采用推导-验证设计评估多种高敏肌钙蛋白截断组合,发现就诊时较低的高敏肌钙蛋白浓度和连续采样较小的绝对变化与较低的心梗可能性和短期心血管事件风险相关。以高敏肌钙蛋白I<6 ng/L且45-120分钟绝对变化<4 ng/L为例,心梗阴性预测值99.5%,30天后续心梗或死亡风险0.2%,56.5%患者可归为低危,外部验证集证实。研究者据此开发了整合就诊时浓度、动态变化和采样时间的风险评估工具,用于估计就诊时心梗概率和30天结局。
要点
- 高敏肌钙蛋白I就诊时<6 ng/L且45-120分钟绝对变化<4 ng/L,心梗阴性预测值99.5%,30天后续心梗或死亡风险0.2%。
- 符合上述标准者占56.5%,可被归为低危人群,外部验证集证实该结果。
- 就诊时高敏肌钙蛋白浓度越低、连续采样绝对变化越小,心梗可能性和短期心血管事件风险越低。
- 研究基于15个国际队列22651例疑似心梗急诊患者,心梗患病率15.3%。
- 研究者开发了整合就诊时高敏肌钙蛋白浓度、动态变化和采样时间的风险评估工具,用于估计就诊时心梗概率和30天结局。
适用人群与场景
- 因症状疑似心肌梗死就诊于急诊的患者,来自15个国际队列,共22651例(推导集9604例,验证集13047例)。
诊断标准与关键阈值
- 高敏肌钙蛋白I就诊时<6 ng/L且45-120分钟(早期连续采样)绝对变化<4 ng/L,心梗阴性预测值99.5%,30天后续心梗或死亡风险0.2%。
研究设计与关键结果
- 研究类型为推导-验证设计,纳入15个国际队列22651例疑似心梗急诊患者,心梗患病率15.3%。
- 就诊时较低的高敏肌钙蛋白浓度和连续采样较小的绝对变化与较低的心梗可能性和较低的短期心血管事件风险相关。
- 高敏肌钙蛋白I<6 ng/L且45-120分钟绝对变化<4 ng/L者,心梗阴性预测值99.5%,30天后续心梗或死亡风险0.2%,56.5%患者归为低危。
- 上述发现在外部验证数据集中得到证实。
证据类型、等级与局限
- 证据类型为基于15个国际队列的推导-验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Data regarding high-sensitivity troponin concentrations in patients presenting to the emergency department with symptoms suggestive of myocardial infarction may be useful in determining the probability of myocardial infarction and subsequent 30-day outcomes.
METHODS: In 15 international cohorts of patients presenting to the emergency department with symptoms suggestive of myocardial infarction, we determined the concentrations of high-sensitivity troponin I or high-sensitivity troponin T at presentation and after early or late serial sampling. The diagnostic and prognostic performance of multiple high-sensitivity troponin cutoff combinations was assessed with the use of a derivation-validation design. A risk-assessment tool that was based on these data was developed to estimate the risk of index myocardial infarction and of subsequent myocardial infarction or death at 30 days.
RESULTS: Among 22,651 patients (9604 in the derivation data set and 13,047 in the validation data set), the prevalence of myocardial infarction was 15.3%. Lower high-sensitivity troponin concentrations at presentation and smaller absolute changes during serial sampling were associated with a lower likelihood of myocardial infarction and a lower short-term risk of cardiovascular events. For example, high-sensitivity troponin I concentrations of less than 6 ng per liter and an absolute change of less than 4 ng per liter after 45 to 120 minutes (early serial sampling) resulted in a negative predictive value of 99.5% for myocardial infarction, with an associated 30-day risk of subsequent myocardial infarction or death of 0.2%; a total of 56.5% of the patients would be classified as being at low risk. These findings were confirmed in an external validation data set.
CONCLUSIONS: A risk-assessment tool, which we developed to integrate the high-sensitivity troponin I or troponin T concentration at emergency department presentation, its dynamic change during serial sampling, and the time between the obtaining of samples, was used to estimate the probability of myocardial infarction on emergency department presentation and 30-day outcomes. (Funded by the German Center for Cardiovascular Research [DZHK]; ClinicalTrials.gov numbers, NCT00470587, NCT02355457, NCT01852123, NCT01994577, and NCT03227159; and Australian New Zealand Clinical Trials Registry numbers, ACTRN12611001069943, ACTRN12610000766011, ACTRN12613000745741, and ACTRN12611000206921.).
参考来源
- Neumann JT, Twerenbold R, Ojeda F, et al. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019. PMID: 31242362. doi:10.1056/NEJMoa1803377
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。